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SUMMARY. Hepatitis C virus (HCV) can be classified into
seven distinct genotypes that are associated with differing
pathologies and respond differently to antiviral therapy. In
the UK, genotype 1 and 3 are present in approximately
equal proportions. Chronic infection with HCV genotype 3
is associated with increased liver steatosis and reduced
peripheral total cholesterol levels, which potentially influ-
ences peripheral immune responses. To understand these
differences, we investigated host gene transcription in
peripheral blood mononuclear cells by microarray and
quantitative PCR in patients with genotype 1 (n = 22) or
genotype 3 infection (n = 22) and matched healthy con-
trols (n = 15). Enrichment of genes involved in immune
response and inflammatory pathways were present in
patients infected with HCV genotype 1; however, no differ-
ences in genes involved in lipid or cholesterol metabolism
were detected. This genotype-specific induction of genes is
unrelated to IL28B genotype or previous treatment failure.
Our data support the hypothesis that genotype 1 infection
drives a skewed Type I interferon response and provides a
foundation for future investigations into the host–pathogen
interactions that underlie the genotype-specific clinical out-
comes of chronic HCV infection.
Keywords: genotype, HCV, IFN, interferon-stimulated genes,
transcriptomics.
INTRODUCTION
Hepatitis C virus (HCV) is a highly diverse human patho-
gen that is prevalent worldwide. The virus has been classi-
fied into seven distinct genotypes, which are approximately
30% divergent at the nucleotide sequence level [1]. The
genotypes segregate according to geographical distribution,
with certain genotypes widely distributed across the globe.
In the UK, genotypes 1 and 3 (gt1 and gt3, respectively)
predominate and have approximately equivalent preva-
lence [2,3]. From a clinical point of view, the distribution
of HCV genotypes is of great importance due to the distinc-
tive clinical outcomes associated with gt1 or gt3 infection.
The response to antiviral therapies is influenced by HCV
genotype. Gt1 infections have a lower sustained virological
response (SVR) rate when treated with combination pegy-
lated interferon (IFN)a and ribavirin (40–50% compared to
70–80% for gt3) [4,5]. This effect of HCV genotype on
treatment outcome differs depending on the specific antivi-
ral drugs employed. A recent phase III clinical trial of the
pan-genotypic direct acting antiviral sofosbuvir identified a
higher rate of relapse in gt3-infected patients, suggesting
that gt3 HCV may be relatively more difficult to treat when
using IFN-free regimes [6]. HCV also exerts genotype-spe-
cific effects on host cell lipid metabolism. Gt3 infections are
associated with an increased prevalence of liver steatosis
and reduced serum cholesterol concentration, both of
which resolve following successful viral clearance [7–10].
These genotype-specific clinical manifestations are indepen-
dent of known negative predictors of treatment response
[5] and co-morbidities associated with liver steatosis [10].
The genotype-specific decrease in peripheral serum cho-
lesterol levels provides a potential mechanism through
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which HCV could modulate peripheral immune cells in a
genotype-specific manner during chronic infection. Periph-
eral cholesterol levels are known to play an important role
in regulating proinflammatory immune responses within
immune cells [11,12]. This raises the possibility that gt3
HCV, by reducing peripheral cholesterol levels, also reduces
the proinflammatory effects exerted by peripheral immune
cells. Studies investigating the interaction between chronic
HCV infection and peripheral blood immune cells have iden-
tified a proinflammatory signature associated with elevated
interferon-stimulated genes (ISGs) [13], as well as elevated
expression of proinflammatory cytokines [14]. However,
these studies have focussed exclusively on infection with gt1
HCV and fail to address potential genotype-specific periph-
eral blood mononuclear cell (PBMC) responses. In this study,
we set out to explore distinctive transcriptional profiles
induced by different HCV genotypes in PBMCs.
MATERIALS AND METHODS
Clinical samples
Clinical samples were used with informed consent conform-
ing to the ethical guidelines of the 1975 Declaration of Hel-
sinki and study protocols were approved by the West of
Scotland Research Ethics Committee. Blood samples were
obtained from a cohort of patients with chronic hepatitis C
and healthy volunteers (Table 1). Exclusion criteria included
co-infection with other viruses (hepatitis B virus or HIV),
non-HCV related liver disease, active antiviral therapy, meta-
bolic disorders, medication affecting lipid metabolism, current
intravenous drug use, chronic alcohol use and a body mass
index (BMI) >30. Participants were assessed for HCV risk fac-
tors, HCV infection status (anti-HCV antibodies, viral load
and virus genotype) and markers of hepatic inflammation/
cirrhosis (alanine aminotransferase levels and transient elas-
tography [FibroScan]). Participants were classified as having
no/minimal fibrosis (FibroScan score <7.1 kPa), fibrosis (Fi-
broScan score 7.1–12.5 kPa) or cirrhosis (FibroScan score
>12.5 kPa) [15]. Statistical significance was calculated using
GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA).
RNA extraction
RNA was extracted from PBMCs following separation over
a density gradient (Histopaque-1077; Sigma-Aldrich, Gil-
lingham, UK). Total RNA was extracted using RNeasy Mi-
nicolumns with on-column DNase-digestion (Qiagen,
Manchester, UK) following manufacturer’s guidelines. RNA
quality and quantity were assessed by NanoDrop 1000
(Thermo Scientific) (Thermo Fisher Scientific, Waltham,
MA, USA) and 2200 TapeStation (Agilent Technologies,
Santa Clara, CA, USA) instruments.
Microarray analysis
RNA (150 ng) was hybridized onto modified Agilent
4 9 44K microarrays containing 201 additional probes,
Table 1 Clinical data
Healthy controls Genotype 1 Genotype 3
n 15 22 22
Male:Female 10:5 15:7 19:3
Caucasian:Asian 15:0 22:0 19:3
Age 44.0 (37.1–50.9) 45.1 (42.5–47.7) 40.6 (37.7–43.6)
BMI* 25.2 (23.2–27.1) 25.4 (24.3–26.6) 25.1 (23.5–26.7)
rs12979860 (CC:CT:TT) n/d 5:14:3 6:8:2†
Previous Treatment Failure (Y:N) n/a 11:11 4:18
Viral Load (1 9 106 IU/mL)* n/a 1.5 (0.7–2.2) 2.1 (0.6–3.6)
FibroScan (kPA) n/d 13.7 (6.4–21.1) 14.6 (7.3–21.9)
Serum ALT (IU/mL) 33.5 (23.6–43.4) 110.6 (41.6–179.6)‡ 127.7 (46.0–209.5)‡
Serum Cholesterol (mmol/L) 5.4 (5.0–5.8) 5.0 (4.6–5.4) 3.9 (3.4–4.4)‡§
Serum Total/HDL Cholesterol 4.6 (3.9–5.2) 3.8 (3.3–4.3) 3.9 (3.2–4.6)
Haemoglobin (g/L) 146 (135–157) 150 (143–156) 150 (140–159)
Platelets (1 9 109/L) 265 (216–313) 232 (186–278) 189 (162–217)‡
White Cell Count (1 9 109/L) 6.6 (6.0–7.3) 6.4 (5.6–7.2) 6.7 (5.8–7.5)
Lymphocytes (1 9 109/L) 2.0 (1.8–2.3) 2.2 (1.8–2.6) 2.1 (1.8–2.4)
Neutrophils (1 9 109/L) 3.9 (3.3–4.4) 3.5 (2.9–4.0) 3.9 (3.2–4.5)
All values are given as the mean with the 95% confidence interval in brackets with n/a signifying not applicable and n/d
signifying not done. *For viral load n = 41 (22 gt1 and 21 gt3); for BMI n = 57 (15 healthy control, 21 gt1 and 21 gt3).
†Genotype information was unavailable for six gt3-infected patients. Significant differences (P-value<0.05) are denoted as
‡versus the ‘Healthy Control’ group or §versus the ‘Genotype 1’ group.
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corresponding to 119 genes previously not found on the
array (Agilent Technologies, Santa Clara, CA, USA). Raw
data were extracted using Feature Extraction software (Ag-
ilent Technologies, Santa Clara, CA, USA), and the gener-
ated text files were processed and analysed with
ChipInspector (Genomatix Software, Munich, Germany).
Differentially regulated genes were selected with a cut-off
fold change of 2 (in either direction) and a signal intensity
of >100 in one of the biological groups.
Clustering and gene-annotation enrichment analysis
Gene-annotation enrichment analysis was carried out with
DAVID Bioinformatics Resource 6.7 [16], using the Agilent
HumanGenomeCGH44K background gene set (for micro-
array data), and adjusting for multiple testing by the Ben-
jamini–Hochberg procedure. Data were clustered in R
using the log-transformed microarray signal values with
the hclust package (utilizing agglomerative clustering) and
visualized by heatmap.2 (from the gplots package).
Reverse transcription and quantitative real-time PCR
(Q-PCR)
Total RNA was reverse transcribed with the SuperScript
VILOTM cDNA Synthesis kit (Life Technologies, Paisley, UK)
according to manufacturer’s instructions. Microarray
results were validated by Q-PCR using TaqMan assays
(Life Technologies, Paisley, UK; Table S1). HPRT1 was used
as a reference gene, and data were analysed using the
comparative threshold cycle method [17]. Statistical signifi-
cance was calculated using the nonparametric Kruskal–
Wallis test with Dunn’s multiple comparison post-test
using GraphPad Prism 5.
RESULTS
Genotype-specific transcriptional changes are observed in
known ISGs but not genes related to lipid metabolism
To investigate potential genotype-specific differences in
PBMC transcription, we selected a subgroup of chronically
infected patients (gt1 n = 8 and gt3 n = 8) who were
matched by age, gender and had low FibroScan scores (to
exclude any transcriptional changes associated with fibro-
sis or cirrhosis). We utilized Agilent 4 9 44K microarrays
modified to detect additional genes, involved in lipid meta-
bolic processes that are absent in the original array. A
total of 42 differentially expressed genes were identified; 37
were up-regulated in the gt1 samples and 5 were up-
regulated in the gt3 samples (Fig. 1 and Table S2). This
small number of differentially expressed genes highlights
the subtle difference between chronic infection with either
HCV gt1 or gt3. Sample clustering on the basis of the
log-transformed microarray signal values from these 42
differentially regulated genes failed to separate the different
genotypes although a subgroup of gt1-infected samples did
form a distinct cluster (Fig. 1). This cluster was statistically
significant when analysed by multiscale bootstrap resam-
pling (data not shown). This implies that at least a propor-
tion of patients infected with gt1 HCV are characterized by
a distinct peripheral transcriptional profile.
The majority of the differentially expressed genes are
known ISGs and play important roles in pro-inflammatory
immune responses to viral infections. The largest differen-
tial transcription was observed for interferon alpha-induc-
ible protein 27 (IFI27; up-regulated 6.0-fold in HCV gt1
infection; Table S2). Sarasin-Filipowicz and colleagues
Fig. 1 Heat map of genes identified as differentially
expressed between gt1- (n = 8; blue labels) and gt3-
infected patients (n = 8; red labels). Microarray signal
values were log-transformed, scaled using Z-score (dark
blue denotes higher and dark red denotes lower), and then
clustered based on Euclidean distance metrics using the
hclust R package.
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previously identified genotype-specific transcription of
IFI27 in liver biopsies [18]; however, reports are conflicting
on whether IFI27 transcription is also up-regulated in
PBMC samples from patients with chronic HCV infection
[13,14]. No genes relating to lipid metabolism were identi-
fied as differentially expressed between HCV gt1 and gt3
infection, and only one gene related to lipid signalling was
identified – free fatty acid receptor 2 (FFAR2; up-regulated
2.2-fold in HCV gt1 infection; Table S2), a G-protein-cou-
pled receptor, expressed on leucocytes, that recognizes
short-chain free fatty acids [19].
Enrichment of immune-related pathways and Type I
IFN-responsive genes in gt1-infected patients
To gain further functional understanding of these geno-
type-specific differences, we performed gene-annotation
enrichment analysis. Significant enrichment of gene terms
relating to antiviral pathways and innate immune
responses were identified amongst the 42 differentially
transcribed genes (Fig. 2a). In particular, the gt1-infected
patients demonstrated an enrichment of the immune
response pathway, the inflammatory response pathway
and the antiviral interferon-induced 56K protein family
[20] (Fig. 2a). Although decreased peripheral cholesterol
levels were observed in the gt3-infected patients (Table 1),
no enrichment of lipid or cholesterol metabolic pathways
was observed.
To further analyse these differentially transcribed genes,
we matched the ISGs to published gene sets generated
following stimulation of PBMCs with Type I IFN, Type II
IFN, interleukin (IL)12 or TNFa, respectively [21]. The
ISGs identified as having genotype-specific expression were
all classified as being induced by Type I IFN, and genes
induced exclusively by Type II IFN or TNFa were absent
(Fig. 2b).
Patients infected with HCV gt1 have elevated peripheral
ISG transcription but comparable IFN transcription to
gt3-infected patients
To validate the microarray findings, we selected three of the
identified genotype-specific genes (interferon-induced protein
with tetratricopeptide repeats 1 (IFIT1), ISG15 ubiquitin-like
modifier (ISG15) and radical S-adenosyl methionine domain
containing 2 (RSAD2)) and analysed their expression by
Q-PCR in the full cohort of patients chronically infected with
either HCV gt1 (n = 22) or gt3 (n = 22). We also analysed a
group of age- and gender-matched uninfected controls
(n = 15). The infected patients showed no significant differ-
ences in viral load, liver function tests or FibroScan scores.
Gt3 infection was associated with significantly reduced
serum cholesterol compared to the uninfected controls and
gt1 infection, consistent with previous studies [7–10], as
well as a significantly reduced platelet count compared to
the uninfected controls (Table 1).
We detected a statistically significant increase in tran-
scription of IFIT1, ISG15 and RSAD2 in gt1-infected
patients compared to healthy controls, which was absent
or reduced in gt3-infected patients (Fig. 3). This elevated
transcription of ISGs in gt1-infected patients (geometric
mean fold change vs healthy controls: IFIT1 = 2.50,
ISG15 = 2.55 and RSAD2 = 2.46) validates the micro-
array results and demonstrates an association between
HCV gt1 and elevated transcription of pro-inflammatory
ISGs in the periphery.
To explore the possibility that elevated expression of IFNs
in PBMCs induces the ISGs in chronically infected patients,
we profiled the transcription of the Type I IFNs IFNA2 and
IFNB1, the Type II IFN IFNG, and the Type III IFN IFNL2.
No significant differences were observed in the transcrip-
tion levels of any of the IFNs between the three groups
(Fig. 3). The transcription of both Type I and Type III IFNs
were very low across all groups, and indeed transcription
was undetectable in a number of samples, suggesting that
IFNs are unlikely to be driving the elevated ISG transcrip-
tion in gt1-infected patients.
Genotype-specific transcriptional profiles are independent
of previous treatment failure and unfavourable IL28B
genotype
Previous studies have identified elevated ISG expression in
the liver [18,22] and PBMCs [23] as predictors of response
to IFN outcome. This elevated ISG expression is also associ-
ated with the unfavourable IL28B ‘CT’ and ‘TT’ genotypes
[24]. We therefore sought to examine whether the
differences we observed between gt1 and gt3 infections
(a) (b)
Fig. 2 Pathway analysis of the
differentially expressed genes identified
from microarray analysis (gt1, n = 8;
gt3, n = 8). (a) Enriched terms from
DAVID analysis ranked by corrected
P-value. (b) Classification of identified
IFN-stimulated genes using published
sets of genes induced by Type I IFN,
Type II IFN or TNFa in PBMC [21].
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were simply due to differences in the number of individuals
with previous treatment failure or in the balance of IL28B
genotypes.
The number of patients who had previously failed
IFN-based therapy was larger in the gt1-infected group
compared to the gt3-infected group (11 vs 4; P-
value = 0.055), as was expected based on the genotypic
differences in treatment response rates. Despite this, the
transcription levels of IFIT1, ISG15 and RSAD2 between
previous treatment failures vs treatment na€ıve individuals
were similar (Fig. 4a). The gt1- and gt3-infected patient
groups had similar proportions of individuals with favour-
able ‘CC’ and unfavourable ‘CT/TT’ genotypes (Table 1).
No differences in the transcription levels of IFIT1, ISG15
and RSAD2 were observed between individuals with
favourable or unfavourable IL28B genotypes (Fig. 4b).
These results imply that HCV gt1 may influence peripheral
immune cells and induce elevated ISG transcription
independent of the described effects of treatment response
phenotype or IL28B genotype.
DISCUSSION
Profiling the transcriptional changes in PBMCs associated
with specific HCV genotypes illuminates genotype-specific
host–pathogen interactions underlying the known clinical
features of chronic HCV infection associated with particular
genotypes. Using a group of age- and gender-matched
patients, selected on the basis of low FibroScan scores to
minimize any changes associated with fibrosis or cirrhosis,
we identified distinct changes in ISG and immune-related
gene transcription within PBMCs from patients infected
with either HCV gt1 or gt3. Chronic infection with HCV
gt1 was associated with elevated transcription of genes
induced by Type I IFNs and involved in immune response
and inflammatory response pathways.
Our results confirm previous studies that have identified
the presence of ongoing proinflammatory gene induction
in PBMCs from patients with chronic HCV infection
[13,14]. Furthermore, our results demonstrate that this
proinflammatory induction is exaggerated in patients
infected with HCV gt1. Importantly, the elevated transcrip-
tion we observed is unrelated to differences in the propor-
tion of individuals with ‘favourable’ or ‘unfavourable’
IL28B genotype or the proportion of patients who have
previously failed IFN-based therapy, both of which are
associated with elevated expression of ISGs [25].
The ISGs identified in our study with elevated transcrip-
tional in PBMCs from patients with gt1 infection include a
number of genes that have previously been identified in
transcriptomic studies of HCV-infected liver biopsies
[18,22,25,26]. These studies compared liver transcriptomes
between patients who achieved SVR with patients who failed
to respond to IFN-based therapies and demonstrated that
higher expression of ISGs is associated with poor response to
therapy [18,22,25,26]. Indeed, pre-existing induction of
ISGs predicts treatment response with greater accuracy than
Fig. 3 Validation of microarray results and transcription of
IFNs using Q-PCR in gt1- (n = 22) and gt3-infected
patients (n = 22), and healthy controls (n = 15). For
IFNA2 n = 17 gt1, 19 gt3 and 11 healthy controls; for
IFNB1 n = 10 gt1, 10 gt3 and six healthy controls; and
for IFNL2 n = 8 gt1, 10 gt3 and eight healthy controls.
Plots show geometric mean with 95% confidence interval.
*denotes P-value <0.05 and ***denotes P-value <0.001.
(a) (b)
Fig. 4 Transcription of genotype-
specific genes IFIT1, ISG15 and RSAD2.
(a) Impact of previous treatment failure
comparing treatment naive patients
(n = 29) and patients who have
previously failed IFN-based therapy
(n = 15). (b) Impact of IL28B genotype
comparing patients with the favourable
‘CC’ genotype (n = 11) and patients
with the unfavourable ‘CT/TT’
genotypes (n = 27). Plots show
geometric mean with 95% confidence
interval.
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the widely used IL28B genotype [25]. While these studies
failed to specifically address genotype-specific transcriptional
changes within the liver, when treatment response was
excluded, viral genotype had the next biggest influence on
differential gene transcription [22].
In the liver, the elevated transcription of ISGs includes a
number of negative regulators of IFNa signalling pathways,
such as ubiquitin-specific peptidase 18 (USP18), which
inhibits further IFN signalling and is thought to contribute
to the lack of IFNa-induced gene induction in treatment
nonresponders [27,28]. Strong IFN responses have also been
hypothesized to limit the development of robust T-cell
immune responses during the establishment of chronic HCV
infection [29]. Our results suggest that a general elevation of
PBMC ISG transcription occurs in gt1-infected patients. This
is in agreement with the conclusion by Sarasin-Filipowicz
and colleagues that patients infected with HCV gt1 more
frequently have increased expression of ISGs in the liver,
which provides a plausible explanation for the relatively
poor response to IFN-based therapies in these patients [18].
It is perhaps noteworthy that gt1 infection is associated with
spontaneous viral clearance during acute infection [30]. The
strong pro-inflammatory responses induced by HCV gt1 may
aid clearance during early acute infection but hinder IFN
signalling once chronic infection is established.
Despite observing a significant level of hypocholestero-
lemia in gt3-infected patients, we did not observe changes in
genes involved in lipid metabolism. While in vitro studies
have identified alterations in metabolic gene expression
induced by HCV gt3 proteins [31,32], our results demon-
strate that such transcriptional changes are not apparent in
PBMCs. It is possible that changes in lipid metabolism may
only occur within liver hepatocytes despite systemic
reduction in total cholesterol levels. Alternatively, genotype-
specific differences in lipid metabolism may only be evident
at a post-transcriptional level. Clark and colleagues have
previously identified a gt3-specific decrease in the serum
levels of metabolites involved in the late stages of cholesterol
synthesis, which resolve upon successful response to
therapy, indicating that HCV gt3 is able to directly perturb
cholesterol biosynthesis at a post-transcriptional level [33].
While the elevation of ISG transcription is evident in
PBMC samples from gt1-infected patients, the mechanisms
underlying this induction are not understood. A key question
raised from our study is why gt1 and gt3 mediate different
transcriptional responses? Although it is likely that reduced
peripheral cholesterol levels act to reduce pro-inflammatory
responses of peripheral immune cells, as described previously
[11,12], this fails to explain potential genotype-specific differ-
ences observed in transcriptomic studies of the liver [18,22].
No differences in the transcription of Type I, II, or III IFNs
were observed between any of the study groups, suggesting
that alternative immune signalling pathways drive the
induction of ISGs. Future studies should address whether
gt1- or gt3-specific genetic sequences are responsible for driv-
ing elevated ISG transcription.
In summary, our data are consistent with the hypothesis
that gt1 infection drives a skewed Type I IFN response.
These transcriptional differences may shed light on possible
mechanisms underlying the distinctive clinical manifesta-
tions of these two HCV genotypes. Our study lays the foun-
dation for further analysis of dysregulation of host cell
factors by the distinct HCV genotypes.
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